Premarket Predictability Act of 2011
Latest action · Oct 18, 2011 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedOct 14, 2011
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Premarket Predictability Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services (HHS) to assign a tracking number to a medical device upon submission of: (1) an application for an exemption of a device for investigational use, (2) a request to classify a device, or (3) a premarket report or notification related to a device. Requires the Secretary to use the tracking number to record interactions between the Secretary and applicant with respect to the device.
Directs the Secretary to: (1) assign a reviewer with prior review experience with the type of of device or technology involved or other relevant expertise to review an application for an exemption of a device for investigational use, and (2) evaluate whether the investigational study can be conducted ethically with reasonable risk in determining whether to grant an exemption for investigational use.
Prohibits the Secretary from disapproving an application because the investigation does not or may not meet any requirement relating to the approval or clearance of a device because the Secretary believes that a different clinical testing design or plan could produce data more relevant to an approval or clearance decision.
Revises the procedures relating to submission of an application to investigate a class II or a class III device, which may include a plan for determining whether the device is substantially equivalent to or is at least as safe and effective as a legally marketed device that is not subject to premarket approval requirements.
Sets forth requirements for the Secretary to meet in determining the least burdensome appropriate means of evaluating medical device effectiveness that would have a reasonable likelihood of resulting in approval.
Requires the Secretary to document the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding device review, approval, or exemption. Sets forth appeal procedures. Requires the Secretary to regularly publish detailed decision summaries for each clearance of a device not requiring premarket approval.
Cosponsors 20
Members who signed on, in the order they did. Signatures ran from Oct 14, 2011 to Jan 31, 2012; 12 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-LA | Bill Cassidy | Original | Oct 14, 2011 |
| R-KY | Brett Guthrie | Original | Oct 14, 2011 |
| R-CA | Brian P. Bilbray | Original | Oct 14, 2011 |
| R-MN | Erik Paulsen | Original | Oct 14, 2011 |
| D-PA | Jason Altmire | Original | Oct 14, 2011 |
| R-TX | Joe Barton | Original | Oct 14, 2011 |
| R-NJ | Leonard Lance | Original | Oct 14, 2011 |
| R-TN | Marsha Blackburn | Original | Oct 14, 2011 |
| R-TX | Michael C. Burgess | Original | Oct 14, 2011 |
| R-MI | Mike Rogers | Original | Oct 14, 2011 |
| R-GA | Phil Gingrey | Original | Oct 14, 2011 |
| R-OH | Robert E. Latta | Original | Oct 14, 2011 |
| R-OR | Greg Walden | Nov 30, 2011 | |
| R-TX | John Abney Culberson | Nov 30, 2011 | |
| R-MI | Dan Benishek | Dec 16, 2011 | |
| R-MO | W. Todd Akin | Dec 16, 2011 | |
| R-SC | Mick Mulvaney | Jan 18, 2012 | |
| R-WA | Cathy McMorris Rodgers | Jan 23, 2012 | |
| R-IN | Todd Rokita | Jan 25, 2012 | |
| D-UT | Jim Matheson | Jan 31, 2012 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Oct 14, 2011 |
| Health Subcommittee | Referred Oct 18, 2011 |
Actions 3
Everything that happened, newest first.
- Oct 18, 2011Referred to the Subcommittee on Health.
- Oct 14, 2011Introduced in House
- Oct 14, 2011Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the page H6977.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to provide predictability, consistency, and transparency to the premarket review process.
- Short Titles as Introduced
- Premarket Predictability Act of 2011
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Government ethics and transparency, public corruption
- Government information and archives
- Health
- Health technology, devices, supplies
- Medical ethics
- Medical research
- Research ethics
Text 1
Each version as it was printed, newest first.
- Oct 14, 2011Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.